Baseline demographic and disease characteristics*
| . | N = 779 . |
|---|---|
| Age | |
| Years, median (range) | 65 (20-90) |
| <65, n (%) | 375 (48) |
| ≥65-75, n (%) | 252 (32) |
| ≥75, n (%) | 152 (20) |
| Sex | |
| Male, n (%) | 528 (68) |
| ECOG performance status, n (%) | |
| 0 | 364 (47) |
| 1 | 367 (47) |
| 2 | 48 (6) |
| Prior treatment status, n (%) | |
| Relapsed/refractory | 688 (88) |
| Prior lines of therapy, median (range) | 2 (1-12) |
| ≥3 prior lines, n (%) | 232 (30) |
| Prior hematopoietic stem cell transplant | 37 (5) |
| Treatment-naïve | 91 (12) |
| Race, n (%) | |
| Asian | 322 (41) |
| White | 417 (54) |
| Other | 20 (3) |
| Black or African American | 5 (0.6) |
| Native Hawaiian or Pacific Islander | 2 (0.3) |
| Multiple | 1 (0.1) |
| Missing/not reported/unknown | 12 (2) |
| Region, n (%) | |
| Asia | 305 (39)† |
| Australia/New Zealand | 301 (39) |
| European Union | 99 (13) |
| North America | 74 (10) |
| Diagnosis, n (%) | |
| Non-Hodgkin lymphoma | 276 (35) |
| Mantle-cell lymphoma | 145 (19) |
| Follicular lymphoma | 59 (8) |
| Marginal zone lymphoma | 25 (3) |
| Diffuse large B-cell lymphoma | 45 (6) |
| Other‡ | 2 (0.3) |
| CLL/SLL | 225 (29) |
| WM | 253 (33) |
| Other (hairy cell leukemia, n = 12; Richter transformation, n = 13) | 25 (3) |
| History of atrial fibrillation | 55 (7) |
| History of hypertension | 270 (35) |
| History of skin cancers§ | 83 (11) |
| . | N = 779 . |
|---|---|
| Age | |
| Years, median (range) | 65 (20-90) |
| <65, n (%) | 375 (48) |
| ≥65-75, n (%) | 252 (32) |
| ≥75, n (%) | 152 (20) |
| Sex | |
| Male, n (%) | 528 (68) |
| ECOG performance status, n (%) | |
| 0 | 364 (47) |
| 1 | 367 (47) |
| 2 | 48 (6) |
| Prior treatment status, n (%) | |
| Relapsed/refractory | 688 (88) |
| Prior lines of therapy, median (range) | 2 (1-12) |
| ≥3 prior lines, n (%) | 232 (30) |
| Prior hematopoietic stem cell transplant | 37 (5) |
| Treatment-naïve | 91 (12) |
| Race, n (%) | |
| Asian | 322 (41) |
| White | 417 (54) |
| Other | 20 (3) |
| Black or African American | 5 (0.6) |
| Native Hawaiian or Pacific Islander | 2 (0.3) |
| Multiple | 1 (0.1) |
| Missing/not reported/unknown | 12 (2) |
| Region, n (%) | |
| Asia | 305 (39)† |
| Australia/New Zealand | 301 (39) |
| European Union | 99 (13) |
| North America | 74 (10) |
| Diagnosis, n (%) | |
| Non-Hodgkin lymphoma | 276 (35) |
| Mantle-cell lymphoma | 145 (19) |
| Follicular lymphoma | 59 (8) |
| Marginal zone lymphoma | 25 (3) |
| Diffuse large B-cell lymphoma | 45 (6) |
| Other‡ | 2 (0.3) |
| CLL/SLL | 225 (29) |
| WM | 253 (33) |
| Other (hairy cell leukemia, n = 12; Richter transformation, n = 13) | 25 (3) |
| History of atrial fibrillation | 55 (7) |
| History of hypertension | 270 (35) |
| History of skin cancers§ | 83 (11) |
Percentages may not always add to 100 because of rounding.
Includes 265 (34%) patients enrolled at study sites within China.
Includes 1 patient with “B lineage lymphoma” and 1 patient with “indolent lymphoma.”
Includes basal cell carcinoma (n = 40), squamous cell carcinoma (n = 20), skin cancer, unspecified (n = 16), squamous cell carcinoma of the skin (n = 12), malignant melanoma (n = 10), and Bowen disease (n = 5). Some patients had multiple skin cancers.